Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach™ is a natural product that will help address global concerns around the overuse of antibiotics in animals and their feed that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Latest news All news
The securities of Anatara Lifesciences have been placed in Trading Halt Session State at the request of the Company, pending a release of an announcement by the Company.
Please click here to view the ASX announcement.
This month PAC Partners initiated analyst coverage on Anatara Lifesciences.
PAC has initiated coverage with a Buy rating and price target of $1.36/share.
To download the full report, please click here.